Oral misoprostol alone, compared with oral misoprostol followed by oxytocin, in women induced for hypertension of pregnancy: A multicentre randomised trial
BJOG: An International Journal of Obstetrics & Gynaecology · 2024
DOI: 10.1111/1471-0528.17839 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2024. Verfasst von Shuchita Mundle und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India. Hauptthemen laut MEDLINE: Misoprostol, Oxytocin, Oxytocics, Cesarean Section. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Foreign, Commonwealth and Development Office, National Institute for Health and Care Research.
Abstract (Originalsprache)
Objective
To assess whether, in those requiring continuing uterine stimulation after cervical ripening with oral misoprostol and membrane rupture, augmentation with low‐dose oral misoprostol is superior to intravenous oxytocin.
Design
Open‐label, superiority randomised trial.
Setting
Government hospitals in India. Population Women who were induced for hypertensive disease in pregnancy and had undergone cervical ripening with oral misoprostol, but required continuing stimulation after artificial membrane rupture.
Methods
Participants received misoprostol (25 micrograms, orally, 2‐hourly) or titrated oxytocin through an infusion pump. All women had one‐to‐one care; fetal monitoring was conducted using a mixture of intermittent and continuous electronic fetal monitoring. Main outcome measures Caesarean birth.
Results
A total of 520 women were randomised and the baseline characteristics were comparable between the groups. The caesarean section rate was not reduced with the use of misoprostol (misoprostol, 84/260, 32.3%, vs oxytocin, 71/260, 27.3%; aOR 1.23; 95% CI 0.81–1.85; P = 0.33). The interval from randomisation to birth was somewhat longer with misoprostol (225 min, 207–244 min, vs 194 min, 179–210 min; aOR 1.137; 95% CI 1.023–1.264; P = 0.017). There were no cases of hyperstimulation in either arm. The rates of fetal heart rate abnormalities and maternal side effects were similar. Fewer babies in the misoprostol arm were admitted to the special care unit (10 vs 21 in the oxytocin group; aOR 0.463; 95% CI 0.203–1.058; P = 0.068) and there were no neonatal deaths in the misoprostol group, compared with three neonatal deaths in the oxytocin arm. Women's acceptability ratings were high in both study groups.
Conclusions
Following cervical preparation with oral misoprostol and membrane rupture, the use of continuing oral misoprostol for augmentation did not significantly reduce caesarean rates, compared with the use of oxytocin. There were no hyperstimulation or significant adverse events in either arm of the trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.
- Department of Women's and Children's Health, University of Liverpool, Liverpool, Merseyside, UK.
- Gynuity Health Projects, New York, New York, USA.
- The Patient-Centered Outcomes Research Institute, Washington, District of Columbia, USA.
- Department of Obstetrics and Gynaecology, Government Medical College, Nagpur, Maharashtra, India.
- Department of Obstetrics and Gynaecology, Daga Memorial Women's Government Hospital, Nagpur, Maharashtra, India.
ORCID-Profile: Jill Durocher
Förderung
- Medical Research Council
- Foreign, Commonwealth and Development Office
- National Institute for Health and Care Research
- Wellcome Trust
Zitieren
APA
Mundle, S., Lightly, K., Durocher, J., Bracken, H., Tadas, M., Parvekar, S., Shivkumar, P. V., Faragher, B., Easterling, T., Leigh, S., Turner, M., Alfirevic, Z., Winikoff, B., & Weeks, A. D. (2024). Oral misoprostol alone, compared with oral misoprostol followed by oxytocin, in women induced for hypertension of pregnancy: A multicentre randomised trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17839
Vancouver
Mundle S, Lightly K, Durocher J, Bracken H, Tadas M, Parvekar S, et al. Oral misoprostol alone, compared with oral misoprostol followed by oxytocin, in women induced for hypertension of pregnancy: A multicentre randomised trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2024. doi:10.1111/1471-0528.17839
BibTeX
@article{Mundle2024,
author = {Mundle, Shuchita and Lightly, Kate and Durocher, Jill and Bracken, Hillary and Tadas, Moushmi and Parvekar, Seema and Shivkumar, Poonam Varma and Faragher, Brian and Easterling, Thomas and Leigh, Simon and Turner, Mark and Alfirevic, Zarko and Winikoff, Beverly and Weeks, Andrew D},
title = {Oral misoprostol alone, compared with oral misoprostol followed by oxytocin, in women induced for hypertension of pregnancy: A multicentre randomised trial},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2024},
doi = {10.1111/1471-0528.17839}
}
EUVIMED